Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eglandin (alprostadil) duration and antibody-mediated rejection in ABO-incompatible living donor liver transplantation
KCT0006115Phase 4Not yet recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Vasostenoon in humoral rejection, sponsored by Mitsubishi Tanabe Pharma Corporation. Planned start May 2021; status: not yet recruiting.
02
Drugs
Vasostenoon
03
Conditions
humoral rejection
Beyond the preview
Go deeper on KCT0006115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006115.